Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker ASMB · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 16, 2026 | A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Participants With Mi… NCT07850999 · Mild Hepatic Imparement ABI-6250 | ASMB Assembly Biosciences | Phase 1 | Not yet recruiting | 20 | Apr 2027 | Registry ↗ |
| Aug 13, 2026 | A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chron… NCT07762027 · Chronic Hepatitis D Infection ABI-6250, ABI-6250 | ASMB Assembly Biosciences | Phase 2 | Not yet recruiting | 80 | Jun 2027 | Registry ↗ |
| Mar 30, 2026 | A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Parti… NCT06385327 · Recurrent Genital Herpes Simplex Type 2 ABI-5366, ABI-5366 Placebo | ASMB Assembly Biosciences | Phase 1 | Completed | 115 | Feb 3, 2026 | Registry ↗ |
| Mar 23, 2026 | A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects an… NCT06698575 · Recurrent Genital Herpes Simplex Type 2 ABI-1179, ABI-1179 Placebo | ASMB Assembly Biosciences | Phase 1 | Completed | 103 | Jan 19, 2026 | Registry ↗ |
| Dec 4, 2025 | A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy Participants NCT06740474 · Hepatitis Delta Virus, Hepatitis D ABI-6250, Placebo | ASMB Assembly Biosciences | Phase 1 | Completed | 40 | Jul 8, 2025 | Registry ↗ |
| Jul 23, 2025 | A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With… NCT06384131 · Chronic Hepatitis B ABI-4334, Placebo | ASMB Assembly Biosciences | Phase 1 | Completed | 20 | Apr 15, 2025 | Registry ↗ |
| Nov 14, 2023 | A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chroni… NCT04820686 · Chronic Hepatitis B VBR, AB-729 | ASMB Assembly Biosciences | Phase 2 | Terminated | 65 | Mar 30, 2023 | Registry ↗ |
| Oct 6, 2023 | A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B V… NCT04781647 · Chronic Hepatitis B ABI-H0731, ETV | ASMB Assembly Biosciences | Phase 2 | Terminated | 54 | Dec 2, 2022 | Registry ↗ |
| Sep 13, 2023 | A First in Human Study to Assess Safety, Tolerability, Pharmacokinetics of ABI-4334 in Healthy Subj… NCT05569941 · Chronic Hepatitis B ABI-4334 Tablet, ABI-4334 Placebo | ASMB Assembly Biosciences | Phase 1 | Completed | 54 | Apr 12, 2023 | Registry ↗ |
| Jun 29, 2023 | A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-H3733 in Subjects Wit… NCT05414981 · Chronic Hepatitis B ABI-H3733, Placebo | ASMB Assembly Biosciences | Phase 1 | Completed | 31 | Apr 24, 2023 | Registry ↗ |
| Apr 19, 2023 | A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients NCT03780543 · Chronic Hepatitis B standard of care (SOC) Nucleoside reverse transcriptase inh… | ASMB Assembly Biosciences | Phase 2 | Terminated | 92 | Apr 26, 2021 | Registry ↗ |
| Oct 20, 2022 | A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis… NCT04454567 · Chronic Hepatitis B ABI-H0731, Placebo | ASMB Assembly Biosciences | Phase 2 | Terminated | 2 | Apr 8, 2021 | Registry ↗ |
| Sep 15, 2022 | A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection NCT04398134 · Chronic Hepatitis B ABI-H2158, Placebo | ASMB Assembly Biosciences | Phase 2 | Terminated | 88 | Oct 14, 2021 | Registry ↗ |
| Mar 19, 2021 | ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis NCT03923478 · Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic… ABI-M201, Placebo | ASMB Assembly Biosciences | Phase 1 | Terminated | 15 | Jan 20, 2021 | Registry ↗ |
| Feb 17, 2021 | A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infecti… NCT03576066 · Chronic Hepatitis B ABI-H0731, SOC NUC | ASMB Assembly Biosciences | Phase 2 | Completed | 73 | Jul 5, 2019 | Registry ↗ |
| Jan 28, 2021 | A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-posit… NCT03577171 · Chronic Hepatitis B ABI-H0731, SOC ETV | ASMB Assembly Biosciences | Phase 2 | Completed | 25 | Jun 21, 2019 | Registry ↗ |
| Jan 27, 2021 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABI-H3733 in Healthy Adults NCT04271592 · Chronic Hepatitis B ABI-H3733 Liquid Oral Dosage Form, ABI-H3733 Solid Oral Dos… | ASMB Assembly Biosciences | Phase 1 | Completed | 120 | Nov 3, 2020 | Registry ↗ |
| Jan 27, 2021 | A Study of ABI-H2158 in Healthy Volunteers and Patients With Chronic Hepatitis B NCT03714152 · Chronic Hepatitis B ABI-H2158, Placebo for ABI-H2158 | ASMB Assembly Biosciences | Phase 1 | Completed | 80 | Nov 23, 2020 | Registry ↗ |
| Jan 12, 2021 | A Study to Evaluate the Mass Balance Absorption and AME of VBR NCT04637139 · Chronic Hepatitis B Vebicorvir (VBR) | ASMB Assembly Biosciences | Phase 1 | Completed | 6 | Dec 22, 2020 | Registry ↗ |
| Mar 4, 2020 | A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H… NCT04142762 · Chronic Hepatitis B ABI-H2158, Itraconazole | ASMB Assembly Biosciences | Phase 1 | Completed | 80 | Jan 12, 2020 | Registry ↗ |
| Nov 29, 2019 | A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults NCT04083716 · Chronic Hepatitis B ABI-H2158 Reference Formulation, ABI-H2158 Test Formulation | ASMB Assembly Biosciences | Phase 1 | Completed | 15 | Oct 5, 2019 | Registry ↗ |
| Apr 4, 2019 | A Study in Healthy Volunteers and Patients With Chronic Hepatitis B NCT02908191 · Chronic Hepatitis B ABI-H0731, Placebo for ABI-H0731 | ASMB Assembly Biosciences | Phase 1 | Completed | 86 | Mar 31, 2018 | Registry ↗ |
| Jul 6, 2018 | Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B NCT03109730 · Chronic Hepatitis B ABI-H0731, Placebo for ABI-H0731 | ASMB Assembly Biosciences | Phase 1/2 | Completed | 38 | Mar 31, 2018 | Registry ↗ |
23 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 5:33 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances